Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming S
PALO ALTO, Calif.--(BUSINESS WIRE)--#AML--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today its plans to present on the company’s myeloid biology research and clinical stage programs at...
Source: pharmiweb.com